| Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients. (NCT01565889) | Gilead Sciences | 2012-03-01 |
| Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial (NCT01492504) | Bristol-Myers Squibb | 2012-02-07 |
| A Registration Study to Evaluate the Performance of CHIRON® RIBA® HCV 3.0 SIA in HCV Antibody Detection (NCT01582594) | Johnson & Johnson Medical, China | 2012-02-01 |
| Hepatitis C Translating Initiatives for Depression Into Effective Solutions (NCT01143896) | VA Office of Research and Development | 2012-02-01 |
| An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients (NCT01467505) | Vertex Pharmaceuticals Incorporated | 2012-02-01 |
| TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy (NCT01485991) | Janssen R&D Ireland | 2012-02-01 |
| Identification of Hepatitis C Virus (HCV) Specific T Cells (NCT01534728) | Institut National de la Santé Et de la Recherche Médicale, France | 2012-02-01 |
| A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients (NCT01497834) | Bristol-Myers Squibb | 2012-01-01 |
| Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection (NCT01492426) | Bristol-Myers Squibb | 2012-01-01 |
| Psychobiological Characterization of Depression in Hepatitis C (NCT01492478) | Centro Hospitalar Lisboa Norte | 2012-01-01 |
| A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients (NCT01466790) | Janssen R&D Ireland | 2012-01-01 |
| Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C (NCT01467492) | Vertex Pharmaceuticals Incorporated | 2012-01-01 |
| Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations (NCT01517529) | University of Cincinnati | 2012-01-01 |
| Phase 3 Study of Sofosbuvir and Ribavirin (NCT01497366) | Gilead Sciences | 2011-12-01 |
| Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection (NCT01231685) | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2011-12-01 |
| Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1 (NCT01446250) | Debiopharm International SA | 2011-12-01 |
| Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C (NCT01448044) | Bristol-Myers Squibb | 2011-12-01 |
| A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV) (NCT01467479) | Vertex Pharmaceuticals Incorporated | 2011-12-01 |
| A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study (NCT01323244) | Janssen R&D Ireland | 2011-12-01 |
| A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C (NCT01482390) | Hoffmann-La Roche | 2011-11-30 |
| HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network (NCT01474811) | University of North Carolina, Chapel Hill | 2011-11-01 |
| Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients (NCT01469884) | Irmandade Santa Casa de Misericórdia de Porto Alegre | 2011-11-01 |
| Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C (NCT01740089) | Biocad | 2011-11-01 |
| Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults (NCT01458054) | GlaxoSmithKline | 2011-09-27 |
| BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C (NCT01389323) | Bristol-Myers Squibb | 2011-09-01 |
| Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects (NCT01445795) | Bristol-Myers Squibb | 2011-09-01 |
| Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805 (NCT01424540) | GlaxoSmithKline | 2011-09-01 |
| GS-7977 With Ribavirin for Hepatitis C (SPARE) (NCT01441180) | National Institute of Allergy and Infectious Diseases (NIAID) | 2011-09-01 |
| Efficacy, Safety and Adherence of Patients Infected With Hepatitis C Virus in Retreat With INFERGEN (Interferon Alfacon1) (NCT01426204) | Closter Pharma | 2011-09-01 |
| Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection (NCT01350648) | National Institutes of Health Clinical Center (CC) | 2011-08-23 |
| Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing (NCT01447680) | G & W Laboratories Inc. | 2011-08-01 |
| Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B (NCT01429155) | Henry Ford Health System | 2011-08-01 |
| Identification of Viral Variants Involved in the Transmission of Hepatitis C and Characterization of Antigenic and Functional Properties of Their Envelope Glycoproteins (NCT02574884) | University Hospital, Tours | 2011-08-01 |
| Does Vitamin D Improves Sustained Virologic Response (SVR) in Genotype 2,3 Chronic Hepatitis C Patients? (NCT01146626) | Ziv Hospital | 2011-08-01 |
| Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers (NCT01427504) | University of Colorado, Denver | 2011-08-01 |
| Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013) (NCT01390428) | Merck Sharp & Dohme LLC | 2011-07-28 |
| 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection (NCT01349465) | Janssen R&D Ireland | 2011-07-04 |
| A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients (NCT01387958) | Novartis Pharmaceuticals | 2011-07-01 |
| Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism (NCT01415141) | University of Vermont | 2011-07-01 |
| Open-Label Hepatic Impairment Study (NCT01497327) | Gilead Sciences | 2011-07-01 |
| A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients (NCT01330316) | Boehringer Ingelheim | 2011-07-01 |
| Reducing Hepatitis C Virus (HCV)/Human Immunodeficient Virus (HIV) Risk Behaviors Among Injection Drug Users in China (NCT01647191) | Shanghai Mental Health Center | 2011-07-01 |
| A Methadone Maintenance Treatment Outcome Study in Three Provinces in China (NCT01315054) | Centers for Disease Control and Prevention | 2011-05-01 |
| WEUSKOP5410: Observational Study in ENABLE Clinical Trials (NCT01458080) | GlaxoSmithKline | 2011-05-01 |
| Behavioral Science Aspects of Rapid Test Acceptance (NCT01317784) | California State University, Long Beach | 2011-05-01 |
| Reinfection and Long Term Outcomes in Intravenous Drug Users (IVDUs) After Hepatitis C Treatment (NCT01329952) | Pennine Acute Hospitals NHS Trust | 2011-05-01 |
| Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003) (NCT01329913) | Merck Sharp & Dohme LLC | 2011-05-01 |
| A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006) (NCT01335607) | Merck Sharp & Dohme LLC | 2011-04-01 |
| Comparison of Selenium Levels in HCV- Infected Patients at Different Stages of Disease (NCT01355107) | University Hospital Freiburg | 2011-04-01 |
| Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1) (NCT01343888) | Boehringer Ingelheim | 2011-04-01 |
| Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2) (NCT01297270) | Boehringer Ingelheim | 2011-04-01 |
| Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants (NCT01318694) | Debiopharm International SA | 2011-03-01 |
| Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin (NCT01309932) | Bristol-Myers Squibb | 2011-03-01 |
| TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir. (NCT01336829) | Tibotec Pharmaceuticals, Ireland | 2011-03-01 |
| TMC435-TiDP16-C116 - Relative Bioavailability and Food Effect Study (NCT01308606) | Tibotec Pharmaceuticals, Ireland | 2011-03-01 |
| Adult-to-Adult Living Donor Transplant Cohort Study (NCT01619475) | Arbor Research Collaborative for Health | 2011-02-01 |
| HCV (Hepatitis C Virus) Viral and Host Genotyping (IL28B, Interleukin 28B) in China (NCT01293279) | Peking University People's Hospital | 2011-02-01 |
| An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy (NCT01281839) | Janssen R&D Ireland | 2011-02-01 |
| An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients (NCT01289782) | Janssen R&D Ireland | 2011-02-01 |
| Pilot Study of Hepatitis C Virus Entry Inhibitor (ITX 5061) in Liver Transplant Recipients (NCT01292824) | University of Birmingham | 2011-02-01 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (NCT01306617) | AbbVie (prior sponsor, Abbott) | 2011-02-01 |
| A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects (NCT01332552) | GlaxoSmithKline | 2011-01-14 |
| The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing (NCT01280825) | University of Chicago | 2011-01-14 |
| Drug-Drug Interaction Study Between Telaprevir and Buprenorphine (NCT01275599) | Vertex Pharmaceuticals Incorporated | 2011-01-01 |
| Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection (NCT01273948) | Peregrine Pharmaceuticals | 2011-01-01 |
| Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C (NCT01274208) | Shaare Zedek Medical Center | 2011-01-01 |
| HCV Virions Bound Proteins (NCT02795403) | Hospices Civils de Lyon | 2011-01-01 |
| TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers (NCT01269294) | Tibotec Pharmaceuticals, Ireland | 2011-01-01 |
| Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders (NCT01273064) | Conatus Pharmaceuticals Inc. | 2011-01-01 |
| Increasing Viral Testing in the Emergency Department (NCT01419899) | Rhode Island Hospital | 2011-01-01 |
| Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds (NCT01285050) | Johns Hopkins University | 2011-01-01 |
| Association Between Hepatitis C Infection and Renal Cell Carcinoma (NCT01405183) | Henry Ford Health System | 2011-01-01 |
| Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic Cirrhosis (NCT01289951) | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | 2010-12-01 |
| VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir (NCT01253551) | Tibotec BVBA | 2010-12-01 |
| A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients. (NCT01277692) | GlaxoSmithKline | 2010-11-03 |
| Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C (NCT01327729) | BioGeneric Pharma | 2010-11-01 |
| Clinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral Therapy (NCT01258686) | Bukwang Pharmaceutical | 2010-11-01 |
| A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) (NCT01221298) | AbbVie (prior sponsor, Abbott) | 2010-10-01 |
| Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants (NCT01215643) | Debiopharm International SA | 2010-10-01 |
| Baclofen to Reduce Alcohol Use in Veterans With HCV (NCT01008280) | VA Office of Research and Development | 2010-10-01 |
| TMC435 HPC1004 - Phase I Study Investigating the Pharmacokinetics of TMC435 in Healthy Chinese Volunteers (NCT01224197) | Tibotec Pharmaceuticals, Ireland | 2010-10-01 |
| Feasibility of a Hepatitis C Virus (HCV) Decision-Making Intervention Among HIV-infected Adults (NCT01472354) | University of Massachusetts, Worcester | 2010-10-01 |
| Safety Study of Raltegravir in HIV/HCV Co-infected Patients (NCT01225705) | University Hospital, Bonn | 2010-10-01 |
| Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants (NCT01180790) | Alexion Pharmaceuticals, Inc. | 2010-09-01 |
| Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults (NCT01165359) | National Institute of Allergy and Infectious Diseases (NIAID) | 2010-09-01 |
| Study of the Impact of Nitazoxanide on Chronic Hepatitis Patients (NCT01197157) | National Liver Institute, Egypt | 2010-09-01 |
| Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects (NCT01200420) | Santaris Pharma A/S | 2010-09-01 |
| Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users (NCT01105611) | St. James's Hospital, Ireland | 2010-08-01 |
| Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment (NCT01183169) | Debiopharm International SA | 2010-08-01 |
| Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population (NCT02601976) | Getz Pharma | 2010-08-01 |
| Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants (NCT02366286) | Mayo Clinic | 2010-07-27 |
| Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection (NCT01182298) | National Institute of Allergy and Infectious Diseases (NIAID) | 2010-07-01 |
| Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV) (NCT01134952) | London Health Sciences Centre | 2010-06-01 |
| Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED) (NCT01181804) | Merck Sharp & Dohme LLC | 2010-06-01 |
| Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives (Levonorgestrel And Ethinyl Estradiol) (NCT00918476) | Pfizer | 2010-06-01 |
| Brief Intervention for Drug Misuse in the Emergency Department (NCT01124591) | Rhode Island Hospital | 2010-06-01 |
| Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients (NCT01473849) | Sociedad Española de Trasplante Hepático | 2010-05-01 |
| Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling (NCT01217359) | University of North Carolina, Chapel Hill | 2010-05-01 |
| TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients (NCT01202825) | Tibotec Pharmaceuticals, Ireland | 2010-04-01 |
| Proteogenomic Monitoring and Assessment of Liver Transplant Recipients (NCT01644903) | Northwestern University | 2010-04-01 |